Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
Our Science
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Jun 15, 2023

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

May 10, 2023

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

May 03, 2023

Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results

Apr 26, 2023

Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

Apr 11, 2023

Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023

Mar 21, 2023

Cerevel Therapeutics to Present at the Stifel 2023 CNS Days

Mar 02, 2023

Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference

Feb 22, 2023

Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Feb 01, 2023

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023

Jan 09, 2023

Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 21

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- Darigabat
- CVL-231
- CVL-936
Investors & MediaInvestors & Media
- Overview
- News & Events
- Stock
- Financials
- Governance
- Resources
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy
FCOI
Early Access Program (EAP) Policy

© 2023 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.